Literature DB >> 12688400

Acetylcholinesterase inhibitor (donepezil hydrochloride) reduces heart rate variability.

Yukitaka Masuda1, Atushi Kawamura.   

Abstract

An acetylcholinesterase inhibitor (donepezil hydrochloride) has recently been used for the treatment of senile dementia of Alzheimer type. The effect of this acetylcholinesterase inhibitor on the autonomic nervous control of the heart was investigated in 17 patients with senile dementia of Alzheimer type. Donepezil administration did not change the plasma concentration of norepinephrine or epinephrine. Twenty-four hour electrocardiogram monitoring was performed, and heart rate variability before and 6 weeks after treatment with donepezil (5 mg per orally) was determined. The heart rate averaged over 24 h was reduced slightly from 74.1 +/- 2.7 beats/min before treatment to 71.1 +/- 2.3 beats/min after treatment. Low (0.04-0.15 Hz) and high (0.15-0.40 Hz) frequency components were reduced significantly with treatment. Ultralow (0.0001-0.003 Hz) and very low (0.003-0.04 Hz) frequency components were not affected. The reduction in the high frequency (41.9 +/- 7.4%) component was greater (p < 0.03) than the reduction in the low frequency (18.6 +/- 10.7%) component. It therefore appears that acetylcholinesterase inhibitor reduces the 1-30 s modulation of heart rate variability but that it has no influence on the much longer 1 min-1 h fluctuation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12688400

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  9 in total

Review 1.  Pharmacologic modulation of parasympathetic activity in heart failure.

Authors:  Monali Y Desai; Mari A Watanabe; Abhay A Laddu; Paul J Hauptman
Journal:  Heart Fail Rev       Date:  2011-03       Impact factor: 4.214

2.  Gastric electrical activity and cardiovascular risk factors in relation to autonomic nervous function, hormonal responses, and health-related lifestyles in young men.

Authors:  Mutsuhiro Nakao; Mariko Nishikitani; Kyoko Nomura; Kanae Karita; Eiji Yano
Journal:  J Gastroenterol       Date:  2006-09       Impact factor: 7.527

3.  Effect of oral administration of zanapezil (TAK-147) for 21 days on acetylcholine and monoamines levels in the ventral hippocampus of freely moving rats.

Authors:  Izzettin Hatip-Al-Khatib; Katsunori Iwasaki; Yoshitaka Yoshimitsu; Takashi Arai; Nobuaki Egashira; Kenichi Mishima; Tomoaki Ikeda; Michihiro Fujiwara
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

4.  The effect of donepezil treatment on cardiovascular mortality.

Authors:  K Sato; R Urbano; C Yu; F Yamasaki; T Sato; J Jordan; D Robertson; A Diedrich
Journal:  Clin Pharmacol Ther       Date:  2010-07-21       Impact factor: 6.875

5.  Cardioprotection and anticholinesterases in patients with Alzheimer's disease: time for reappraisal.

Authors:  Fiammetta Monacelli; Patrizio Odetti; Marina Sartini; Antonello Parodi; Claudio Brunelli; Gianmarco Rosa
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2014-02-14

6.  Reduced sympathetic response to head-up tilt in subjects with mild cognitive impairment or mild Alzheimer's dementia.

Authors:  Marte Rognstad Mellingsæter; Torgeir Bruun Wyller; Anette Hylen Ranhoff; Nenad Bogdanovic; Vegard Bruun Wyller
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2015-03-13

7.  Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics.

Authors:  Ramón Cacabelos
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570

Review 8.  From Genome-Wide Association Studies to Cardiac Electrophysiology: Through the Maze of Biological Complexity.

Authors:  Koen T Scholman; Veronique M F Meijborg; Carolina Gálvez-Montón; Elisabeth M Lodder; Bastiaan J Boukens
Journal:  Front Physiol       Date:  2020-05-27       Impact factor: 4.566

9.  Impact of the ambulatory blood pressure monitoring profile on cognitive and imaging findings of cerebral small-vessel disease in older adults with cognitive complaints.

Authors:  Yong S Shim; Hae-Eun Shin
Journal:  J Hum Hypertens       Date:  2021-02-15       Impact factor: 3.012

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.